Switch theme
Sign up to access all valuation multiples
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
2018
195
LTM Revenue $4.0M
LTM EBITDA -$125M
-$123M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
TScan Therapeutics has a last 12-month revenue of $4.0M and a last 12-month EBITDA of -$125M.
In the most recent fiscal year, TScan Therapeutics achieved revenue of $2.8M and an EBITDA of -$120M.
TScan Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See TScan Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $21.0M | $2.8M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$80.1M | -$120M | XXX | XXX | XXX |
| EBITDA Margin | -381% | -4252% | XXX | XXX | XXX |
| Net Profit | -$66.2M | -$89.2M | XXX | XXX | XXX |
| Net Margin | -315% | -3168% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, TScan Therapeutics's stock price is $1.
TScan Therapeutics has current market cap of $70.2M, and EV of -$123M.
See TScan Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$123M | $70.2M | XXX | XXX | XXX | XXX | $-1.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, TScan Therapeutics has market cap of $70.2M and EV of -$123M.
TScan Therapeutics's trades at -30.6x LTM EV/Revenue multiple, and 1.0x LTM EBITDA.
Analysts estimate TScan Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for TScan Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$123M | XXX | XXX | XXX |
| EV/Revenue | -43.5x | XXX | XXX | XXX |
| EV/EBITDA | 1.0x | XXX | XXX | XXX |
| P/E | -0.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 1.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpTScan Therapeutics's NTM/LTM revenue growth is 83%
TScan Therapeutics's revenue per employee for the last fiscal year averaged $14K, while opex per employee averaged $0.7M for the same period.
Over next 12 months, TScan Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate TScan Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for TScan Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -87% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -4252% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 49% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -4169% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $14K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1050% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3812% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 4888% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TScan Therapeutics acquired XXX companies to date.
Last acquisition by TScan Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . TScan Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was TScan Therapeutics founded? | TScan Therapeutics was founded in 2018. |
| Where is TScan Therapeutics headquartered? | TScan Therapeutics is headquartered in United States of America. |
| How many employees does TScan Therapeutics have? | As of today, TScan Therapeutics has 195 employees. |
| Who is the CEO of TScan Therapeutics? | TScan Therapeutics's CEO is Dr. Gavin MacBeath, PhD. |
| Is TScan Therapeutics publicy listed? | Yes, TScan Therapeutics is a public company listed on NAS. |
| What is the stock symbol of TScan Therapeutics? | TScan Therapeutics trades under TCRX ticker. |
| When did TScan Therapeutics go public? | TScan Therapeutics went public in 2021. |
| Who are competitors of TScan Therapeutics? | Similar companies to TScan Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of TScan Therapeutics? | TScan Therapeutics's current market cap is $70.2M |
| What is the current revenue of TScan Therapeutics? | TScan Therapeutics's last 12-month revenue is $4.0M. |
| What is the current EBITDA of TScan Therapeutics? | TScan Therapeutics's last 12-month EBITDA is -$125M. |
| What is the current EV/Revenue multiple of TScan Therapeutics? | Current revenue multiple of TScan Therapeutics is -30.6x. |
| What is the current EV/EBITDA multiple of TScan Therapeutics? | Current EBITDA multiple of TScan Therapeutics is 1.0x. |
| What is the current revenue growth of TScan Therapeutics? | TScan Therapeutics revenue growth between 2023 and 2024 was -87%. |
| Is TScan Therapeutics profitable? | Yes, TScan Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
